Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Effector Therapeutics Inc
(NQ:
EFTR
)
1.820
+0.060 (+3.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Effector Therapeutics Inc
< Previous
1
2
Next >
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
February 21, 2023
Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference
January 30, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update
January 05, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 07, 2022
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
October 31, 2022
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
October 26, 2022
Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.